March 23, 2021
Otsuka Pharmaceutical said on March 22 that it has filed a new drug application in Japan for OPC-61815, a prodrug of the vasopressin V 2 receptor antagonist tolvaptan, for the treatment of cardiac edema inadequately controlled with loop diuretics or...read more